海欣股份(600851) - 2024 Q3 - 季度财报

Revenue and Profit - Q3 2024 revenue decreased by 38.14% year-on-year to ¥198,897,708.03, primarily due to a reduction in bulk trade revenue and pharmaceutical production revenue[2] - Net profit attributable to shareholders increased by 52.04% year-on-year to ¥36,890,247.08, mainly driven by increased profits from joint ventures[2] - Total operating revenue for the first three quarters of 2024 was CNY 605,397,522.11, a decrease of 36% compared to CNY 946,698,652.49 in the same period of 2023[14] - Net profit for the first three quarters of 2024 reached CNY 151,965,776.76, an increase of 15% from CNY 131,618,732.09 in 2023[15] - The company reported investment income of CNY 125,694,114.38, up from CNY 115,566,685.23 in the same period last year[15] Earnings Per Share - Basic earnings per share for the current period was ¥0.0306, reflecting a 52.24% increase compared to the same period last year[3] - Basic earnings per share for the first three quarters of 2024 were CNY 0.1149, compared to CNY 0.1043 in 2023[16] Assets and Equity - Total assets as of the end of the reporting period reached ¥5,400,329,491.52, representing a 9.97% increase from the end of the previous year[3] - The total equity attributable to shareholders increased by 10.15% year-on-year to ¥4,367,476,293.53[3] - The total equity attributable to shareholders of the parent company increased to CNY 4,367,476,293.53, up from CNY 3,965,055,449.29 in the previous year[13] - Total assets and equity increased to CNY 5,400,329,491.52, up from CNY 4,910,625,159.28 in 2023[13] Cash Flow - Cash flow from operating activities showed a significant decline of 183.10%, resulting in a net cash outflow of ¥26,382,749.42 for the current period[2] - The net cash flow from operating activities for Q3 2024 was CNY 40,245,051.97, an increase from CNY 35,474,802.50 in Q3 2023[17] - Total cash outflow from operating activities was CNY 674,126,450.67, compared to CNY 989,056,805.57 in Q3 2023[17] - Cash received from sales of goods and services was CNY 650,918,248.99, down from CNY 955,854,221.26 year-over-year[17] Liabilities - The total liabilities of the company were CNY 860,988,453.79, up from CNY 775,286,878.90, which is an increase of approximately 11.02%[12] - The company's short-term borrowings remained stable at CNY 25,000,000.00, unchanged from the previous period[12] Operating Costs and Expenses - Total operating costs for the first three quarters of 2024 were CNY 568,081,089.99, down 37% from CNY 907,740,662.91 in 2023[14] - Research and development expenses for the first three quarters of 2024 were CNY 15,799,227.71, an increase of 17% compared to CNY 13,471,180.04 in 2023[15] Other Financial Metrics - Non-recurring gains and losses totaled ¥2,400,988.30 for the current period, with government subsidies contributing ¥2,501,714.65[4] - The weighted average return on net assets increased by 0.2973 percentage points to 0.9253% for the current period[3] - Other comprehensive income after tax for the first three quarters of 2024 was CNY 342,207,665.57, significantly higher than CNY 94,646,632.77 in the previous year[15] - The company reported a significant decrease in employee compensation payable, which fell to CNY 15,131,396.42 from CNY 31,100,833.02, a reduction of approximately 51.39%[12] Cash and Cash Equivalents - The cash and cash equivalents decreased to CNY 407,421,665.87 from CNY 509,547,074.84, reflecting a decline of approximately 20%[10] - The ending balance of cash and cash equivalents was CNY 383,724,921.68, a decrease from CNY 551,312,552.69 in Q3 2023[18]